Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma

The immunomodulatory drugs (IMiDs) lenalidomide and pomalidomide are highly effective treatments for multiple myeloma. However, virtually all patients eventually relapse due to acquired drug resistance with resistance-causing genetic alterations being found only in a small subset of cases. To identi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Yuen Lam Dora, Ramberger, Evelyn, Bohl, Stephan R., Dolnik, Anna, Steinebach, Christian, Conrad, Theresia, Müller, Sina, Popp, Oliver, Kull, Miriam, Haji, Mohamed, Gütschow, Michael, Döhner, Hartmut, Walther, Wolfgang, Keller, Ulrich, Bullinger, Lars, Mertins, Philipp, Krönke, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866544/
https://www.ncbi.nlm.nih.gov/pubmed/35197447
http://dx.doi.org/10.1038/s41467-022-28515-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866544/
https://www.ncbi.nlm.nih.gov/pubmed/35197447
http://dx.doi.org/10.1038/s41467-022-28515-1

Ejemplares similares